Carbimazole 1.5mg/5ml oral solution

Graves' disease (GD) is an autoimmune condition of the thyroid. The hyperthyroidism manifested by patients affected by this disease is caused by the production of autoantibodies against the thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR), which mimic the effects of the hormone on thyroid cells, thereby stimulating autonomic production of thyroxine and triiodothyronine. Deciding on a therapeutic approach to this condition presents intricate dilemmas for both clinicians and patients. Each of the three available treatment modalities is grounded in evidence-based medicine, affirming its efficacy. This systematic review and meta-analysis aimed to assess the effect of carbimazole (CBM), radioactive iodine (RAI), and surgery in treating GD and provide evidence-based recommendations for healthcare providers regarding the optimal management of the condition based on a comprehensive analysis of effectiveness, safety, patient satisfaction, and recovery outcomes. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We used the PubMed and Google Scholar databases to conduct a thorough web search for articles published between January 2019 and September 2023. The meta-analysis was carried out using Resource Manager (Revman) 5.4.1. The study found that propylthiouracil (PTU) or methimazole/carbimazole (MMI/CBM) treatment increases the risk of hyperlipidemia in patients with hyperthyroidism. Once in a euthyroid state, glucose tolerance increases; for children with GD, a computer model for customized dosing has been created. To sum up, CBM, surgery, and RAI are all useful treatment options for GD. Using steroids in conjunction with radiation therapy may help prevent Graves' ophthalmopathy (GO).

Abstract licence: CC BY

The incidence of carbimazole-induced liver injury (DILI) in patients treated for hyperthyroidism is infrequent, ranging from 0.1% to 0.5%. Whilethe injury usuallyfollows a cholestatic pattern, the condition can also present with mixed or cytolytic features, driven by either immune-mediated responses or the metabolic involvement of cytochrome P450 enzymes.We report the case of a 29-year-old woman with Graves’ disease (free T4: 78 pmol/L) who developed severe hepatotoxicity two weeks after initiating 40 mg/dayof Carbimazole. The patient presented with clinical jaundice and laboratory findings of significant cholestasis. After excluding viral, autoimmune, and structural etiologies, a diagnosis of carbimazole-induced hepatotoxicity was established. Management included immediate cessation of the antithyroid drug, initiation of corticosteroid therapy (1 mg/kg/day), and a session of plasmapheresis to bridge the patient safely toward a thyroidectomy. Liver function showed marked improvement within one week of discontinuation. These findings suggest that when conventional cessation of the drug is insufficient to stabilize rapidly deteriorating liver enzymes, advanced extracorporeal therapies may serve as a crucial bridge to definitive surgical intervention. Ultimately, this report reinforces the necessity of vigilantmonitoring of liverfunction tests during the initiation of carbimazole therapy. By advocating for proactive serial biochemical screening, we aim to standardize safer clinical practices and improve outcomes for patients requiring rapid definitive treatment in the setting of severe, unpredictable, and potentially life-threatening drug-induced liver injury caused by antithyroid medications.

Abstract licence: CC BY

Amiodarone-induced thyrotoxicosis (AIT) is a complex endocrine disorder associated with significant morbidity, particularly in patients with underlying cardiac disease. Type 2 AIT, a destructive thyroiditis, is typically managed with corticosteroids. However, treatment becomes challenging when glucocorticoids are contraindicated. We present the case of a 37-year-old male with atrial fibrillation, dilated cardiomyopathy, and McCune-Albright syndrome who developed persistent biochemical thyrotoxicosis while on amiodarone therapy. Despite suppressed thyroid-stimulating hormone and elevated free thyroxine levels, he remained clinically asymptomatic. A thyroid uptake scan demonstrated low uptake consistent with type 2 AIT, although thyroid receptor antibodies were positive, suggesting possible mixed pathology. Management was complicated by coexisting liver lesions, precluding corticosteroid therapy. The patient was managed with low-dose carbimazole, resulting in gradual normalization of thyroid function. This case highlights the complexity of diagnosing and managing AIT and demonstrates that thionamides may be a viable alternative in selected patients in whom corticosteroids are contraindicated, particularly in cases with overlapping features of type 1 and type 2 AIT.

Abstract licence: CC BY